Intelligence / Healthtech / New Clinical Trials / Sensorion
Sensorion
17 Nov 2026: Trial registered · A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 Gene. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 17 Nov 2026
- Title
- A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 Gene
- Conditions
- GJB2 Gene Mutation, DFNB1A, Congenital Deafness, Hearing Disorders
- Phase
- Phase 1, Phase 2
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- France
- Country
- France
- Reference
- NCT07941115
- Location
- France
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Sensorion
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from France
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.